Novel therapeutic agents for cutaneous T-Cell lymphoma-Reference-Cited by-同舟云学术

Novel therapeutic agents for cutaneous T-Cell lymphoma

Published:2012-05-17 Issue:1 Volume:5 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

Jain Salvia,Zain Jasmine,O’Connor Owen

Abstract

Abstract Mycosis fungoides (MF) and Sezary Syndrome (SS) represent the most common subtypes of primary Cutaneous T-cell lymphoma (CTCL). Patients with advanced MF and SS have a poor prognosis leading to an interest in the development of new therapies with targeted mechanisms of action and acceptable safety profiles. In this review we focus on such novel strategies that have changed the treatment paradigm of this rare malignancy.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

https://link.springer.com/content/pdf/10.1186/1756-8722-5-24.pdf

Reference110 articles.

1. Bradford PT, Devesa SS, Anderson WF: Cutaneous lymphoma incidence patters in the United States: a population based study of 3884 cases. Blood. 2009, 113: 5064-5073. 10.1182/blood-2008-10-184168.

2. Olsen E, Vonderheid E, Pimpinelli N: Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the international society for cutaneous lymphomas (ISCL) and the cutaneous lymphoma task force of the European organization for research and treatment of cancer (EORTC). Blood. 2007, 110: 1713-1722. 10.1182/blood-2007-03-055749.

3. Agar NS, Wedgeworth E, Crichton S: Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised international society for cutaneous lymphomas/European organization for research and treatment of cancer staging proposal. J Clin Oncol. 2010, 28: 4730-4739. 10.1200/JCO.2009.27.7665.

4. Kim YH, Liu HL, Mraz-Gernhard S: Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 1996, 139: 857-866.

5. Horwitz SM, Olsen EA, Duvic M: Review of the treatment of mycosis fungoides and Sezary syndrome: a stage-based approach. J Natl Compr Canc Netw. 2008, 6 (4): 436-442.

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors;Cell Communication and Signaling;2024-02-08

2. Gut microbiota analyses of cutaneous T-cell lymphoma patients undergoing narrowband ultraviolet B therapy reveal alterations associated with disease treatment;Frontiers in Immunology;2024-01-11

3. Class I HDAC Inhibition Leads to a Downregulation of FANCD2 and RAD51, and the Eradication of Glioblastoma Cells;Journal of Personalized Medicine;2023-08-27

4. Improved overall survival over time in advanced stage mycosis fungoides: a cross-sectional study;Leukemia & Lymphoma;2022-06-24

5. Gut dysbiosis in cutaneous T‐cell lymphoma is characterized by shifts in relative abundances of specific bacterial taxa and decreased diversity in more advanced disease;Journal of the European Academy of Dermatology and Venereology;2022-04-19